Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1279-1284

  Salama, Noha N ^a,b,c,d   Segal, Jonathan H ^b,e   Churchwell, Mariann D ^b,f   Patel, Jignesh H ^a,b   Gao, Lihong ^g   Heung, Michael ^b,e   Mueller, Bruce A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Renal Replacement Therapy Kinetics Study Group   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d CAIRO UNIVERSITY   (Egypt)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TOLEDO   (United States)

^g Cubist Pharmaceutical Inc   (United States)

Author keywords

Daptomycin; Gram positive bacteria; Haemodialysis; Pharmacokinetics

Indexed keywords

DAPTOMYCIN; UREA;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PERMEABILITY; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77950248682     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp655     Document Type: Article

References (18)

1. Cubicin. Full Prescribing Information 2008
2. Pai AB, Pai MP. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis 2006; 13: 259-270
3. Salama NN, Segal J, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodial-ysis. Clin J Am Soc Nephrol 2009; 4: 1190-1194
4. Klansuwan N, Ratanajamit C, Kasiwong S, et al. Clearance of vanco-mycin during high-efficiency hemodialysis. J Med Assoc Thai 2006; 89: 986-991
5. Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 2006; 40: 9-14
6. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomy-cin and selected comparators tested against bloodstream Staphylococ-cus aureus isolates from hemodialysis patients. Int J Infect Dis 2009; 13: 291-295
7. Louie A, Kaw P, Liu W, et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45: 845-851
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10, quiz 11-12
9. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-68
10. Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999; 8: 1223-1238
11. Dandekar PK, Tessier PR, Williams P, et al. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneu-moniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy 2004; 50: 11-16
12. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000
13. Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-inter-mediate and-resistant strains. Antimicrob Agents Chemother 2000; 44: 11062-11066
14. Daugirdas JT, Van Stone JC. Physiologic principles and urea kinetic modeling. In: JT Daugirdas, TS Ing, PG Blake (eds). Handbook of Dialysis. Philadelphia: Lippincott Williams &Wilkins, 2001: pp 46-66
15. Benvenuto M, Benziger DP, Yankelev S, et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-3249
16. Woodworth JR, Nyhart EHJ, Brier GL, et al. Single-dose pharmaco-kinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-325
17. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmaco-kinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323
18. Dvorchik BH, Arbeit RD, Chung J, et al. Population pharmacoki-netics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-2807